Daiichi Sankyo gets US patent office to restart review of Seagen patent

Daiichi Sankyo is going back after Seagen in the latest bout of patent infringement accusations.

The Japanese pharma announced Friday that the US Patent and Trademark Office (PTO) has agreed to the company’s request to restart a post-grant review of a Seagen patent.